Your DNA May Determine How Well GLP-1 Medications Work for You

Key Takeaways

• Genetic variants in GLP1R predict weight loss effectiveness on GLP-1 medications
• GIPR variants predict nausea and vomiting side effects, especially with tirzepatide
• The study analyzed 27,885 people and was published in Nature
• This is the first large-scale pharmacogenomic study for GLP-1 drugs
• Personalized dosing based on genetics may replace one-size-fits-all protocols

What Did the Study Find?

Variants in GLP1R predict weight loss response; variants in GIPR predict side effect severity on GLP-1 medications.

23andMe's Research Institute partnered with academic institutions to analyze genetic data from 27,885 participants taking GLP-1 receptor agonist medications. The study identified specific single-nucleotide polymorphisms (SNPs) in the GLP1R gene that correlate with the magnitude of weight loss. People carrying certain variants lost significantly more weight on the same medication and dose than those without the variants.

A separate finding identified variants in the GIPR gene that predict gastrointestinal side effects. This is particularly relevant for tirzepatide (dual GIP/GLP-1 agonist), where nausea and vomiting are the primary reasons patients discontinue treatment. Knowing in advance whether a patient carries these variants could inform which medication a clinician prescribes.

Why Does This Matter for Your Protocol?

Genetic testing could predict your response to GLP-1 drugs before you start, eliminating months of trial and error.

The current standard for GLP-1 prescribing is dose escalation: start low, increase gradually, see what happens. If the medication works, stay the course. If side effects are intolerable, switch. This process takes weeks to months and costs real time and money.

Pharmacogenomic data changes that equation. If a clinician knows before the first injection that a patient's genetics favor semaglutide over tirzepatide, or that a given patient is likely to respond well at a standard dose without needing escalation, the entire protocol becomes more precise. Less guesswork. Fewer wasted weeks. Better outcomes from day one.

T1Rx already runs comprehensive bloodwork panels before initiating protocols. Genetic screening for GLP-1 response is the logical next step in that approach. The tools are not widely available yet, but the science now supports them.

What Are the Limitations?

Genetics explain part of the response variation. Lifestyle, dosing, adherence, and metabolic factors still matter.

This study is a significant advance, but it does not reduce GLP-1 response to a single gene. The identified variants explain a portion of the variation between patients. Other factors, including baseline metabolic health, dietary adherence, activity level, sleep, and stress, still play a role. Genetic data adds a layer of precision to clinical decision-making. It does not replace clinical judgment.

The study population was also predominantly of European ancestry, which means the findings may not generalize equally across all populations. Larger, more diverse studies are needed to validate these associations broadly.

What Does This Mean for the Future of GLP-1 Therapy?

Personalized GLP-1 prescribing based on genetic markers is moving from theory to clinical reality.

The pharmaceutical industry is watching this closely. If genetic testing can predict which patients will respond best to which GLP-1 medication, it changes the economics of prescribing, insurance coverage, and patient selection. It also opens the door to companion diagnostics: a genetic test paired with a specific medication, the way oncology already does with targeted therapies.

For telehealth platforms that already emphasize lab-driven, personalized protocols, this research validates the approach. The direction of travel is clear: more data, more personalization, better results.

The Protocol Starts with Data

The best protocols have always been built on data, not guesswork. Comprehensive bloodwork before starting. Regular monitoring during treatment. And now, genetics adding another layer of precision. The science is catching up to what the best clinicians already practice.

Explore T1Rx GLP-1 protocols. Lab-driven. Clinician-supervised. Built for people who take this seriously.

Frequently Asked Questions

Can I get a genetic test for GLP-1 response right now?

Commercial genetic tests specifically validated for GLP-1 response are not yet widely available. 23andMe's research arm conducted this study, but translating research findings into a clinical product takes additional validation. Ask your provider about emerging pharmacogenomic testing options.

Does this mean GLP-1 drugs do not work for some people?

GLP-1 medications produce weight loss in the vast majority of patients. The genetic variants identified affect the magnitude of response, not whether the drug works at all. Some people lose more weight than others on the same dose. Genetics appears to be one factor explaining that difference.

Should I switch medications based on this study?

Do not change your protocol based on a single study. Discuss any medication changes with your prescribing clinician. This research informs the field but is not yet a clinical decision tool.

Should I stop taking GLP-1 if I have side effects?

Side effects like nausea are common during dose escalation and often resolve. If side effects are persistent or severe, talk to your provider about adjusting your dose or switching medications. Do not discontinue without clinical guidance.